Susquehanna International Group’s Citius Pharmaceuticals CTXR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $22.6K | Buy |
+14,199
| New | +$22.6K | ﹤0.01% | 6139 |
|
|
2025
Q1 | – | Hold |
0
| – | – | – | 6500 |
|
|
2024
Q4 | – | Sell |
-6,603
| Closed | -$82.6K | – | 6270 |
|
|
2024
Q3 | $82.6K | Sell |
6,603
-19,019
| -74% | -$238K | ﹤0.01% | 5175 |
|
|
2024
Q2 | $374K | Buy |
25,622
+25,173
| +5,606% | +$367K | ﹤0.01% | 3926 |
|
|
2024
Q1 | $10.1K | Sell |
449
-5,191
| -92% | -$116K | ﹤0.01% | 5355 |
|
|
2023
Q4 | $107K | Buy |
5,640
+3,660
| +185% | +$69.2K | ﹤0.01% | 5318 |
|
|
2023
Q3 | $33.9K | Sell |
1,980
-4,029
| -67% | -$69K | ﹤0.01% | 5190 |
|
|
2023
Q2 | $180K | Sell |
6,009
-12,371
| -67% | -$371K | ﹤0.01% | 4705 |
|
|
2023
Q1 | $538K | Buy |
18,380
+5,208
| +40% | +$152K | ﹤0.01% | 3727 |
|
|
2022
Q4 | $260K | Buy |
13,172
+10,985
| +502% | +$217K | ﹤0.01% | 4097 |
|
|
2022
Q3 | $66K | Sell |
2,187
-4,848
| -69% | -$146K | ﹤0.01% | 5416 |
|
|
2022
Q2 | $162K | Buy |
7,035
+1,644
| +30% | +$37.9K | ﹤0.01% | 4713 |
|
|
2022
Q1 | $241K | Sell |
5,391
-1,968
| -27% | -$88K | ﹤0.01% | 4605 |
|
|
2021
Q4 | $283K | Sell |
7,359
-3,285
| -31% | -$126K | ﹤0.01% | 4550 |
|
|
2021
Q3 | $540K | Buy |
10,644
+2,351
| +28% | +$119K | ﹤0.01% | 3588 |
|
|
2021
Q2 | $721K | Buy |
8,293
+4,370
| +111% | +$380K | ﹤0.01% | 3434 |
|
|
2021
Q1 | $175K | Buy |
+3,923
| New | +$175K | ﹤0.01% | 4844 |
|
|
2020
Q1 | – | Sell |
-971
| Closed | -$25K | – | 4613 |
|
|
2019
Q4 | $25K | Buy |
+971
| New | +$25K | ﹤0.01% | 3842 |
|